Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Value-Added Medicines

Set Alert for Value-Added Medicines

Harmonization Needed For Complex And Value-Added Drugs

Complex generics and value added medicines share common challenges on harmonization of regulation, lack of incentives and clarity of guidelines, heard delegates to Medicines for Europe’s Regulatory & Scientific Affairs conference.

Europe Regulation

Lilly's Basaglar Becomes A Blockbuster

Quarterly global Basaglar sales rose above $300m for the first time in the fourth quarter of 2019, with full-year turnover pushing the insulin glargine hybrid well into blockbuster territory.

Sales & Earnings Value-Added Medicines

Editor's Note: Tell Us Your Views in Our Customer Survey

We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the format of the content or the method in which you receive and access Generics Bulletin, or if you love it how it is, now is the time to have your voice heard.

Commercial Policy & Regulation

Hikma Lines Up US Hybrid Injectable

Hikma has struck a deal to develop with the UK’s Arecor a ready-to-use injectable that will be filed under the US 505(b)(2) hybrid regulatory pathway.

Deals Value-Added Medicines

Sboul Is Appointed IGBA Chair

Hanan Sboul, secretary general of the Jordanian Association of Pharmaceutical Manufacturers, has been named as chair of the International Generic and Biosimilar medicines Association. She takes over from Jim Keon, president of the Canadian Generic Pharmaceutical Association.

Appointments Generic Drugs

Advanz Sees Mumbai Center As Strategic Strength

Using its Indian back-office function to realize synergies from acquired sales and marketing assets in western Europe forms a key part of Advanz Pharma’s growth strategy.

Business Strategies M & A
See All
UsernamePublicRestriction

Register